No abstract available
MeSH terms
-
Adrenergic Uptake Inhibitors / adverse effects
-
Adrenergic Uptake Inhibitors / pharmacokinetics
-
Adrenergic Uptake Inhibitors / therapeutic use*
-
Animals
-
Antidepressive Agents / adverse effects
-
Antidepressive Agents / pharmacokinetics
-
Antidepressive Agents / therapeutic use*
-
Biological Availability
-
Clinical Trials as Topic
-
Cyclopropanes / adverse effects
-
Cyclopropanes / pharmacokinetics
-
Cyclopropanes / therapeutic use
-
Depressive Disorder, Major / blood
-
Depressive Disorder, Major / drug therapy*
-
Depressive Disorder, Major / psychology
-
Drug Approval / legislation & jurisprudence
-
Duloxetine Hydrochloride
-
Humans
-
Metabolic Clearance Rate
-
Milnacipran
-
Morpholines / adverse effects
-
Morpholines / pharmacokinetics
-
Morpholines / therapeutic use*
-
Reboxetine
-
Thiazepines / adverse effects
-
Thiazepines / pharmacokinetics
-
Thiazepines / therapeutic use
-
Thiophenes / adverse effects
-
Thiophenes / pharmacokinetics
-
Thiophenes / therapeutic use
-
United States
Substances
-
Adrenergic Uptake Inhibitors
-
Antidepressive Agents
-
Cyclopropanes
-
Morpholines
-
Thiazepines
-
Thiophenes
-
tianeptine
-
Duloxetine Hydrochloride
-
Reboxetine
-
Milnacipran